Bortezomib and Temozolomide in Recurrent Glioblastoma With Unmethylated MGMT Promoter (BORTEM-17)
Status:
Recruiting
Trial end date:
2023-08-30
Target enrollment:
Participant gender:
Summary
This phase IB/II trial is designed to investigate the safety and survival benefits for
patients with recurrent glioblastoma with unmethylated MGMT promoter treated with Bortezomib
and Temozolomide in a specific schedule.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Haukeland University Hospital
Collaborators:
Oslo University Hospital St. Olavs Hospital University Hospital of North Norway University of Bergen University of Bonn University of Oslo